Litchfield Hills Research Predicts SLXN FY2025 Earnings

Silexion Therapeutics Corp (NASDAQ:SLXN) – Investment analysts at Litchfield Hills Research issued their FY2025 earnings per share estimates for shares of Silexion Therapeutics in a report released on Monday, December 15th. Litchfield Hills Research analyst T. O’neill expects that the company will post earnings per share of ($3.83) for the year. Litchfield Hills Research currently has a “Buy” rating on the stock. Litchfield Hills Research also issued estimates for Silexion Therapeutics’ Q4 2025 earnings at ($1.17) EPS and FY2026 earnings at ($4.80) EPS.

A number of other analysts have also commented on the stock. Wall Street Zen upgraded shares of Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research raised Silexion Therapeutics to a “hold” rating in a report on Tuesday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $75.00.

Silexion Therapeutics Price Performance

Shares of NASDAQ:SLXN opened at $2.43 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97. The firm has a market cap of $7.61 million, a price-to-earnings ratio of -0.22 and a beta of -0.06. The business has a 50-day simple moving average of $3.01 and a two-hundred day simple moving average of $6.91. Silexion Therapeutics has a fifty-two week low of $2.13 and a fifty-two week high of $51.75.

Silexion Therapeutics (NASDAQ:SLXN) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.52.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.